MONTREAL, July 30, 2018 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V:RLV) (OTCQB:RLLVF) and (Frankfurt: 6BX ) (the “ Company ” or “ Relevium ”), is pleased to announce it has received final listing approval for its Bioganix® Gold Series Nutraceuticals on Walmart.com and the products are currently live and available for purchase.
Relevium received today the final product listing approvals by the quality control team at Walmart.com and has begun selling its Bioganix® Gold Series nutraceutical products. As initially announced on May 3, 2018 the Company had received brand approval from Walmart.com to sell in its marketplace and today the Company received final approval for its initial product listing, which are currently live and available for purchase in the United States.
Bioganix® Gold Series is a unique and exclusive line of nutraceutical supplements designed exclusively for discerning health and wellness Walmart.com shoppers. The Company has launched an initial four (4) SKUs comprised of exclusive formulations from some of the highest volume sellers in the Bioganix® product line . The company’s Bioganix Gold Series products includes; Apple Cider Vinegar Capsules , BioPro Advanced Probiotic, Garcinia Cambogia and Pure Forskolin .
Aurelio Useche, CEO of Relevium stated: “The BioGanix® Gold Series is an exclusive Walmart.com line of nutraceuticals and supplements that gives the Company access to a new consumer base” Mr. Useche continued: “Our expectations for the new brand and the Walmart.com channel are high and we believe we will be able to scale the business and expand our available SKUs considerably faster than through our traditional distribution channels”
Abis Hussain, CMO of Relevium , stated: “In the coming months we will establish a working relationship with Walmart as we market our initial batch of products. Depending on demand, available traffic, conversion rates and ultimately profit margins, we will quickly move to launching additional exclusive products to Walmart.com through our Bioganix® Gold Series Nutraceutical brand”
Shareholders should expect updates on the initial performance Walmart.com in Q2 of this fiscal year.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or brands with a focus on e-commerce in the growing health and wellness sector. The Company, through its wholly-owned subsidiary, Biocannabix Health Corporation, is also incorporating cannabinoids into its nutraceutical strategy and provide its retail customers access to the health benefits of cannabis through its formulations and established brands.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC Email: investors@releviumcorp.com Website: www.releviumtechnologies.com Like us on Facebook Follow us on Twitter Follow us on LinkedIn
